Liquidia

Liquidia is a late-stage clinical biopharmaceutical company that focuses on the development and commercialization of various products using its PRINT technology that enables precise production of drug particles designed to enhance the safety, efficacy, and performance of a range of therapies. It was founded in 2004 and is based in Morrisville, North Carolina.
Liquidia stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Liquidia balance sheet

Report period2018 2019 2020 2021 2022Q3 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Liquidia cash flows

Report period2018 2019 2020 2021 2022Q3 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Liquidia multipliers

Report period2018 2019 2020 2021 2022Q3 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Liquidia profitability

Report period2018 2019 2020 2021 2022Q3 23 TTM
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Liquidia assets
Liquidia cash flows

Liquidia dividend policy

The company doesn't provide dividend

Liquidia shares

TickerNameTypeNominal valueISINPrice
LQDA:USLiquidiaCommon share-US53635D2027$10.89
Liquidia news
12.05.2022
Liquidia's GAAP loss for 3 months of 2022 was $15.943 million, up 73.6% from $9.183 million in the prior year. Revenue increased 13.2% to $3.492 million compared to $3.084 million a year earlier.
17.03.2022
Liquidia's GAAP loss for 2021 was $34.579 million, down 42.1% from $59.763 million the previous year. Revenue increased 17.4 times to $12.853 million from $0.739 million a year earlier.
05.11.2021
Liquidia's GAAP loss for 9M 2021 was $23.016 mln. 2021 was $23.016 million, down 47.3% from $43.676 million in the previous year. Revenues were $9.638 million. The company did not generate revenues a year earlier.
10.08.2021
Liquidia's GAAP loss for 6M 2021 was $15.735 million, down 45.2% from $28.708 million in the prior year. Revenue was $6.459 million. A year earlier, the company had generated no revenue.
General information
Company nameLiquidia
Tags#pharmacy, #biotechnology
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address419 Davis Drive Suite 100 Morrisville, NC 27560 United States
Mailing address419 Davis Drive Suite 100 Morrisville, NC 27560 United States
Websitewww.liquidia.com
Information disclosurewww.sec.gov